Advertisement

Topics

Embosphere® PROstate Post Market Study

2018-05-22 18:49:10 | BioPortfolio

Published on BioPortfolio: 2018-05-22T18:49:10-0400

Clinical Trials [2438 Associated Clinical Trials listed on BioPortfolio]

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

Investigators hypothesis that arterial embolization of men with symptomatic BPH, analogous to uterine fibroid embolization for women, is safe and effective.

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign pros...

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasi...

Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

The primary study objective is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) at 12 months post ...

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in me...

PubMed Articles [2841 Associated PubMed Articles listed on BioPortfolio]

Prostatic artery embolization for benign prostatic hyperplasia: a review.

Over the last several years prostate artery embolization (PAE) has been developed as a minimally invasive technique for the treatment of benign prostatic hyperplasia induced lower urinary tract sympto...

Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results from a Prospective FDA-Approved Investigational Device Exemption Study.

To evaluate the safety and efficacy of prostate artery embolization(PAE) for lower urinary tract symptoms(LUTS) attributed to benign prostatic hyperplasia(BPH).

MRI features after prostatic artery embolization for the treatment of medium- and large-volume benign hyperplasia.

To assess magnetic resonance imaging (MRI) features after prostatic artery embolization (PAE) for the treatment of medium- and large-volume benign prostatic hyperplasia and to correlate prostate volum...

Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study.

This retrospective cohort study evaluated the association between gout and the risk of benign prostatic hyperplasia among men by using data from Taiwan's National Health Insurance Research Database.

Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia.

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, which results in the development of lower urinary tract symptoms that can interfere with a patient's daily acti...

Medical and Biotech [MESH] Definitions

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

An orally active TESTOSTERONE 5-ALPHA-REDUCTASE inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia.

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

More From BioPortfolio on "Embosphere® PROstate Post Market Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial